The key take is that the Mesoblast has a high chance of becoming the standard of care in the US for GVHD in children and probably globally with label extension potential in adults.
note: the company is most likely the standard of care in Japan now for GVHD
plans are in place to hit the ground running and much work has been done to ensure the are ready for Launch pending approval.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.41 |
Change
0.620(34.6%) |
Mkt cap ! $3.084B | |||
| Open | High | Low | Value | Volume |
| $1.90 | $2.48 | $1.90 | $58.82M | 25.68M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 100915 | $2.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.41 | 99 | 1 |
View Market Depth
| Last trade - 16.12pm 18/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |